In this study, we collected 78 EGFR‐mutated SCC patients and matched with ADC patients to compare the efficacy of EGFR‐TKIs, and the results showed that median PFS in EGFR‐mutated SCC and ADC patients treated with icotinib was 12.7 months vs 15.8 months, median OS was 18.5 months vs 24.2 months, and the ORR was 48.7% vs 59.0%. This evidence concerns the gene EGFR and AIDS dementia complex.